Gilead Sciences, Inc. Fundamental Analysis (XETRA: GIS.DE)
Gilead Sciences, Inc. Fundamental Analysis (XETRA: GIS.DE)
Gilead Sciences, Inc. (XETRA: GIS.DE) shows weak financial fundamentals with a PE ratio of -56.94, profit margin of -10.67%, and ROE of -16.37%. The company generates $30.4B in annual revenue with weak year-over-year growth of 2.39%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -0.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze GIS.DE's fundamental strength across five key dimensions:
Efficiency Score
WeakGIS.DE struggles to generate sufficient returns from assets.
Valuation Score
ExcellentGIS.DE trades at attractive valuation levels.
Growth Score
ModerateGIS.DE shows steady but slowing expansion.
Financial Health Score
ModerateGIS.DE shows balanced financial health with some risks.
Profitability Score
WeakGIS.DE struggles to sustain strong margins.
Key Financial Metrics
Is GIS.DE Expensive or Cheap?
P/E Ratio
GIS.DE trades at -56.94 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, GIS.DE's PEG of 0.32 indicates potential undervaluation.
Price to Book
The market values Gilead Sciences, Inc. at 15.56 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 96.77 times EBITDA. This signals the market has high growth expectations.
How Well Does GIS.DE Make Money?
Net Profit Margin
For every $100 in sales, Gilead Sciences, Inc. keeps $-10.67 as profit after all expenses.
Operating Margin
Core operations generate 37.51 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-16.37 in profit for every $100 of shareholder equity.
ROA
Gilead Sciences, Inc. generates $-6.58 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Gilead Sciences, Inc. generates strong operating cash flow of $13.53B, reflecting robust business health.
Free Cash Flow
Gilead Sciences, Inc. generates strong free cash flow of $12.92B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $10.41 in free cash annually.
FCF Yield
GIS.DE converts 7.04% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-56.94
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.32
vs 25 benchmark
P/B Ratio
Price to book value ratio
15.56
vs 25 benchmark
P/S Ratio
Price to sales ratio
6.04
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
2.22
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.27
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.16
vs 25 benchmark
ROA
Return on assets percentage
-0.07
vs 25 benchmark
ROCE
Return on capital employed
0.30
vs 25 benchmark
How GIS.DE Stacks Against Its Sector Peers
| Metric | GIS.DE Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -56.94 | 32.14 | Better (Cheaper) |
| ROE | -16.37% | 550.00% | Weak |
| Net Margin | -10.67% | 30133.00% | Weak |
| Debt/Equity | 2.22 | 0.56 | Weak (High Leverage) |
| Current Ratio | 1.27 | 5.70 | Neutral |
| ROA | -6.58% | 3.00% | Weak |
GIS.DE outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Gilead Sciences, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
20.50%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
6891.00%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
23.94%
Industry Style: Defensive, Growth, Innovation
High Growth